Skip Nav Destination
Issues
15 February 2016
-
Cover Image
Cover Image
At 24 hours after intravenous injection, PLP nanoparticles enabled fluorescence imaging of a tumor with considerable specificity and accuracy at the cellular level. For details, see the article by Muhanna and colleagues on page 961 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Reviews
Cancer Therapy: Clinical
Author Choice
Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors
Amita Patnaik; Glen J. Weiss; John E. Leonard; Drew Warren Rasco; Jasgit C. Sachdev; Terrence L. Fisher; Laurie A. Winter; Christine Reilly; Robert B. Parker; Danielle Mutz; Lisa Blaydorn; Anthony W. Tolcher; Maurice Zauderer; Ramesh K. Ramanathan
Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)
Silvia Stacchiotti; Maria A. Pantaleo; Tiziana Negri; Annalisa Astolfi; Marcella Tazzari; Gian Paolo Dagrada; Milena Urbini; Valentina Indio; Roberta Maestro; Alessandro Gronchi; Marco Fiore; Angelo P. Dei Tos; Elena Conca; Elena Palassini; Bruno Vincenzi; Federica Grosso; Silvana Pilotti; Chiara Castelli; Paolo G. Casali
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
John Sarantopoulos; Geoffrey I. Shapiro; Roger B. Cohen; Jeffrey W. Clark; John S. Kauh; Glen J. Weiss; James M. Cleary; Devalingam Mahalingam; Michael D. Pickard; Hélène M. Faessel; Allison J. Berger; Kristine Burke; George Mulligan; Bruce J. Dezube; R. Donald Harvey
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Didier Meulendijks; Ulrik N. Lassen; Lillian L. Siu; Alwin D.R. Huitema; Vaios Karanikas; Morten Mau-Sorensen; Derek J. Jonker; Aaron R. Hansen; Mary E. Simcox; Kathleen J. Schostack; Dean Bottino; Hua Zhong; Markus Roessler; Suzana M. Vega-Harring; Tiantom Jarutat; David Geho; Karen Wang; Mark DeMario; Glenwood D. Goss; Jan H.M. Schellens
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Michael Andreeff; Kevin R. Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W. Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M. Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks; Wolfgang Jacob; Maria Martinez-Garcia; Alvaro Taus; Martijn P. Lolkema; Emile E. Voest; Marlies H.G. Langenberg; Tania Fleitas Kanonnikoff; Andres Cervantes; Maja J. De Jonge; Stefan Sleijfer; Morten Mau Soerensen; Marlene Thomas; Maurizio Ceppi; Georgina Meneses-Lorente; Ian James; Celine Adessi; Francesca Michielin; Keelara Abiraj; Birgit Bossenmaier; Jan H.M. Schellens; Martin Weisser; Ulrik N. Lassen
Personalized Medicine and Imaging
Triple-Negative versus Non–Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study
Franca Podo; Filippo Santoro; Giovanni Di Leo; Siranoush Manoukian; Clelia de Giacomi; Stefano Corcione; Laura Cortesi; Luca A. Carbonaro; Rubina M. Trimboli; Anna Cilotti; Lorenzo Preda; Bernardo Bonanni; Matilde Pensabene; Laura Martincich; Antonella Savarese; Alma Contegiacomo; Francesco Sardanelli
HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis
Tarek M.A. Abdel-Fatah; Stephanie E.B. McArdle; Devika Agarwal; Paul M. Moseley; Andrew R. Green; Graham R. Ball; A. Graham Pockley; Ian O. Ellis; Robert C. Rees; Stephen Y.T. Chan
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
Cloud P. Paweletz; Adrian G. Sacher; Chris K. Raymond; Ryan S. Alden; Allison O'Connell; Stacy L. Mach; Yanan Kuang; Leena Gandhi; Paul Kirschmeier; Jessie M. English; Lee P. Lim; Pasi A. Jänne; Geoffrey R. Oxnard
Cancer Therapy: Preclinical
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Karina E. Hew; Philip C. Miller; Dorraya El-Ashry; Jun Sun; Alexandra H. Besser; Tan A. Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B. Mills; Joyce M. Slingerland; Fiona Simpkins
Biology of Human Tumors
Global Hypomethylation (LINE-1) and Gene-Specific Hypermethylation (GSTP1) on Initial Negative Prostate Biopsy as Markers of Prostate Cancer on a Rebiopsy
Renata Zelic; Valentina Fiano; Daniela Zugna; Chiara Grasso; Luisa Delsedime; Lorenzo Daniele; Diego Galliano; Andreas Pettersson; Anna Gillio-Tos; Franco Merletti; Lorenzo Richiardi
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients
David Chu; Costanza Paoletti; Christina Gersch; Dustin A. VanDenBerg; Daniel J. Zabransky; Rory L. Cochran; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Sarah Croessmann; Bracha Erlanger; Karen Cravero; Kelly Kyker-Snowman; Berry Button; Heather A. Parsons; W. Brian Dalton; Riaz Gillani; Arielle Medford; Kimberly Aung; Nahomi Tokudome; Arul M. Chinnaiyan; Anne Schott; Dan Robinson; Karen S. Jacks; Josh Lauring; Paula J. Hurley; Daniel F. Hayes; James M. Rae; Ben Ho Park
Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Apurva K. Srivastava; Soumya Jaganathan; Laurie Stephen; Melinda G. Hollingshead; Adam Layhee; Eric Damour; Jeevan Prasaad Govindharajulu; Jennifer Donohue; Dominic Esposito; James P. Mapes; Robert J. Kinders; Naoko Takebe; Joseph E. Tomaszewski; Shivaani Kummar; James H. Doroshow; Ralph E. Parchment
Author Choice
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Laura H. Tang; Brian R. Untch; Diane L. Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J. Allen; David S. Klimstra
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds